Radiojodtherapie des Schilddrüsenkarzinoms

[1]  L. Duntas,et al.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. , 2004, European journal of endocrinology.

[2]  N. Willich,et al.  Multicenter Study Differentiated Thyroid Carcinoma (MSDS) , 2003, Nuklearmedizin.

[3]  P. Bartenstein,et al.  Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. , 2003, Thyroid : official journal of the American Thyroid Association.

[4]  C. Reiners,et al.  Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2) , 2003, Nuklearmedizin.

[5]  S. Chew,et al.  Should high hTg levels in the absence of iodine uptake be treated? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  S. Gulec,et al.  Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Cyrill Burger,et al.  Bicycle exercise stress in PET for assessment of coronary flow reserve: repeatability and comparison with adenosine stress. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  H. Müller-Gärtner,et al.  Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  S. Larson,et al.  Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[10]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[11]  S. Asa,et al.  Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. , 1998, The Journal of clinical endocrinology and metabolism.

[12]  P. Ladenson,et al.  Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma , 1998, Annals of Internal Medicine.

[13]  O. Schober,et al.  Survival of differentiated thyroid carcinoma studied in 500 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Dottorini,et al.  Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.

[16]  A. Pinchera,et al.  Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  M. Schlumberger,et al.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[19]  G. Masarotto,et al.  Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[21]  N. Willich,et al.  External Beam Radiotherapy , 2005 .

[22]  K. Mann,et al.  Pathologie des Schilddrüsenkarzinoms , 2004, Der Onkologe.

[23]  M. Dietlein,et al.  Über- oder Untertherapie des papillären Mikrokarzinoms der Schilddrüse? Überlegungen zur ablativen Radioiodtherapie , 2004 .

[24]  M. Dietlein,et al.  Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 2 , 2004 .

[25]  H. Dralle,et al.  Chirurgie der Schilddrüsenkarzinome , 2004, Der Onkologe.

[26]  N. Willich,et al.  Strahlentherapie des Schilddrüsenkarzinoms , 2004, Der Onkologe.

[27]  M. Dietlein,et al.  Verfahrensanweisung für die Schilddrüsenszintigraphie (Version 2 , 2003 .

[28]  O. Schober,et al.  Should high hTG levels in the absence of iodine uptake be treated? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. , 1996, Cancer.

[30]  R. Segal.  Radioactive Iodine Treatment of Thyroid Carcinoma , 1992 .

[31]  E. Moser,et al.  Radiojodtherapie des differenzierten Schilddrüsenkarzinoms. Empfehlungen der Arbeitsgemeinschaft Therapie der Deutschen Gesellschaft für Nuklearmedizin , 1992 .

[32]  C. Wittekind,et al.  TNM Klassifikation maligner Tumoren , 1987 .